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A B S T R A C T
The purpose of this study was to investigate the effect of ionization of drug on drug solu-
bilization in SMEDDS (self-microemulsifying drug delivery system) prepared using Capmul
MCM and caprylic acid. Solubilization capacity of blank SMEDDS dispersions for danazol,
indomethacin and haloperidol as model drugs was determined. Based on the outcomes of
solubilization capacity study, drug-loaded SMEDDS formulations were prepared and sub-
jected to dispersion/precipitation study and droplet size analysis. Blank SMEDDS dispersions
exhibited the highest solubilization capacity for haloperidol followed by indomethacin and
danazol. Furthermore, the solubilization of the three drugs in blank SMEDDS dispersions
was explained by a modified mathematical model. Dispersion/precipitation studies indi-
cate that drug-loaded SMEDDS formulations exhibited superiority in solubilizing the drugs
in comparison to their respective drug powder. In addition, indomethacin and haloperidol
were found to reduce the droplet size of the microemulsions while danazol did not affect
droplet size formation for drug-loaded SMEDDS formulations. These findings suggest that
ionization of drug affects drug solubilization, droplet size formation, drug loading and drug
dispersion/precipitation profiles for the SMEDDS formulations.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Poorly water-soluble drugs generally display low bioavailability
due to poor aqueous solubility and dissolution rate [1]. For the
development of oral dosage form products, the approaches to
increase solubility or dissolution rate of these drugs for optimal
bioavailability are needed [2]. Among several approaches re-
ported in the literature, self-microemulsifying drug delivery
system (SMEDDS) offers the potential for enhancing absorption
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and subsequently the better bioavailability of poorly water-
soluble drugs by presenting the drug in solubilized form in the
gastrointestinal tract [3–6]. SMEDDS is defined as an isotropic
mixture of oils, surfactants/co-surfactants and drug, which
rapidly forms microemulsion with droplet size typically less
than 200 nm upon oral administration into the gastrointesti-
nal tract [7–9]. The formed microemulsion enhances drug
solubilization by incorporating the drug in lipid/surfactant col-
loidal aggregates formed upon contact with aqueous medium
[10].
Depending on whether the drugs have ionizable groups or
not, poorly water-soluble drugs can be roughly classified into
pH-dependent (weak acidic/basic) and pH-independent (neutral)
drugs [11]. Due to various degree of ionization of drug, the solu-
bilization of the drugs in the lipid/surfactant colloidal aggregates
may be different. Neutral drugs have been suggested to be solu-
bilized in the lipid core while weak acidic/basic drugs have been
suggested to be solubilized in the lipid core as well as at the
surface of the colloidal aggregates due to their surface-active
properties [10,12]. In contrast to neutral drugs which have less
influence on the size and shape of the formed microstruc-
tures, weak acidic/basic drugs may change the size or shape
of the microstructures by interacting with the surface of the
microstructures [8,12]. It has been reported that phospholipid/
isopropylmyristate mixture formed rod-like phospholipid/
isopropylmyristate aggregates upon dispersion in water when
no drug was loaded, while loading fenoprofen acid trans-
formed the phospholipid/isopropylmyristate aggregates into
spherical shape and loading fenoprofen sodium transformed
the aggregates into extremely long rods [13]. Furthermore, the
solubilization capacity for different drugs, upon dispersion of
lipid/surfactant (and/or co-surfactant) systems (e.g., SMEDDS)
in aqueous medium, is expected to be different due to various
intermolecular forces between drug and SMEDDS compo-
nents such as oils and surfactants/co-surfactants used.
In our previous study, SMEDDS based on medium-chain
triglyceride “pre-digestion” products Capmul MCM and ca-
prylic acid coupled with Cremophor RH40 as surfactant was
successfully developed [14]. To further investigate the effect
of ionization of drug on drug solubilization in the SMEDDS,
danazol (MW 338), indomethacin (pKa 4.5, MW 358) and
haloperidol (pKa 8.2, MW 376) were selected as the model
drugs due to their difference in degree of ionization in
aqueous medium but similarity in molecular weight/size. All
three drugs belong to Biopharmaceutical Drug Classification
System (BCS) Class II drugs which have poor aqueous solubil-
ity and high permeability [15]. Danazol is a synthetic steroid
derived from ethisterone; it is a neutral drug with aqueous
solubility of 0.42 μg/ml [16]. Danazol contains no acidic/basic
group in its structure. Therefore, it does not ionize at any pH
and its aqueous solubility is not affected by pH change.
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID)
and is a weak acidic drug with the intrinsic aqueous solubil-
ity of 0.9 μg/ml [17,18]. Indomethacin contains a carboxyl
group which ionizes at high pH and its aqueous solubility is
highly pH dependent. Aqueous solubility of indomethacin
increases dramatically when pH is higher than pKa (e.g.,
630 μg/ml at pH 6.8). Haloperidol is a butyrophenone antipsy-
chotic drug; it is a weak basic drug with the intrinsic aqueous
solubility of 3.5 μg/ml [19,20]. Haloperidol contains a tertiary
amine group which ionizes at low pH and therefore has
pH-dependent solubility and exhibits high aqueous solubility
at low pH (e.g., 1074 μg/ml at pH 1.2).
The SMEDDS studied in this investigation using Capmul
MCM and caprylic acid was first applied to enhance solubili-
zation of a neutral drug (i.e., danazol) [14]. To extend its
application to non-neutral drugs, a weak acidic drug (indo-
methacin) and a weak basic drug (haloperidol) were used as
the model drugs and compared with the results of using
danazol reported from previous studies [14], with the purpose
of addressing the effect of drug ionization on drug solubiliza-
tion behavior upon dispersion of the SMEDDS in aqueousmedia
at various pHs. Solubilization capacity, drug loading, drug
dispersion/precipitation profiles and droplet size formation of
either blank SMEDDS and/or drug-loaded SMEDDS of these three
drugs were determined and compared. In addition, an attempt
was made to evaluate and extend the application of a re-
ported mathematical model to neutral, weak acidic and weak
basic drugs in SMEDDS, which was initially proposed to explain
solubilization of flurbiprofen in surfactant micelles [21]. This
concept of attributing total drug solubilization to four drug-
related species (Du, Di, Du-SMEDDS and Di-SMEDDS) provides a
fundamental understanding of how drug ionization affects drug
solubilization behavior upon dispersion of drug-loaded SMEDDS
in aqueous media at various pHs.
2. Materials and methods
2.1. Materials
Capmul MCM (HLB 4.7) was obtained as a gift from Abitec Cor-
poration (Columbus, OH). The composition of Capmul MCM is
approximately 60% of medium-chain monoglycerides and 40%
of diglycerides, derived from caprylic acid (83%) and capric acid
(17%). Danazol was donated by Sanofi-Aventis Pharmaceutics
(Bridgewater, NJ). Caprylic acid (HLB 1), indomethacin, halo-
peridol, hydrochloric acid (1 N), potassium chloride, potassium
phosphatemonobasic, sodium hydroxide, sodium acetate, acetic
acid, and polyethylene glycol (PEG) 400 were purchased from
VWR (Solon, OH). Cremophor RH40 (HLB 14–16) was supplied
by BASF Corporation (Tarrytown, NJ). All chemicals and sol-
vents were of analytical purity or high performance liquid
chromatography (HPLC) grade and used as received with no
further treatment.
2.2. Analytical methodology for danazol, indomethacin
and haloperidol
Danazol samples were analyzed using a reversed-phase HPLC
method modified from the literature [22]. The HPLC analysis
system for danazol consisted of aWaters 600 controller, aWaters
717 plus autosampler and a Waters 2487 Dual λ detector. The
chromatographic column was C18 Waters Symmetry column
(3.5 μm, 250 mm × 4.6 mm). The mobile phase was a mixture
of acetonitrile and distilled water (80:20, v/v) and the wave-
length was 286 nm.The HPLC analysis system for indomethacin
and haloperidol consisted of a quaternary pump, an
autosampler and a diode array detector (HP1100 Series, Agilent
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Technologies,Wilmington, DE). For analysis of indomethacin,
the chromatographic column was C8 Waters XBridge column
(3.5 μm, 4.6 mm × 150 mm); the mobile phase was a mixture
of methanol and 50 mM sodium acetate buffer (pH 3.5) (70:30,
v/v); the wavelength was 263 nm [23]. For analysis of haloperi-
dol, the chromatographic column was C18 Waters Symmetry
column (3.5 μm, 4.6 mm × 250 mm); the mobile phase was a
mixture of acetonitrile and distilled water (70:30, v/v) and the
wavelength was 250 nm [24]. In all the three cases, the flow
rate was 1 ml/min and the injection volume was 10 μl.
The HPLC methods for danazol, indomethacin and halo-
peridol were found to be reproducible (relative standard
deviation <5%) and accurate.The accuracy was between 98.3%
and 102.4% for danazol, 97.3% and 103.8% for indomethacin
and 97.6% and 104.5% for haloperidol, respectively. For danazol,
the good linear relationship (R2 = 0.9998) was obtained within
the concentration range of 0.47–116.4 μg/ml and the limit of
detection (LOD) was 0.10 μg/ml. For indomethacin, a stan-
dard plot was constructed within the concentration range of
0.44–109.2 μg/ml (R2 = 0.9998) and the LOD was 0.11 μg/ml. For
haloperidol, the good linear relationship (R2 = 0.9999) was ob-
tained within the concentration range of 1.27–101.44 μg/ml and
LOD was 0.20 μg/ml.
2.3. Preparation of blank SMEDDS
The composition of blank SMEDDS was selected based on
the conclusion of phase diagrams reported elsewhere [14].
Two representative blank SMEDDS formulations were pre-
pared and coded as blank F5:5 and F4.5:4.5:1 in this
investigation. As listed in Table 1, blank F5:5 and F4.5:4.5:1
were composed of 50% and 45% Capmul MCM:CA (1:1) as
lipid phase as well as 50% and 45% Cremophor RH40 as
surfactant, respectively. In addition to the lipid and surfac-
tant used, 10% PEG 400 as the co-surfactant was included in
blank F4.5:4.5:1. The lipid phase was prepared by mixing
Capmul MCM and caprylic acid (1:1 w/w) on a wrist-action
shaker (Burrell Scientific, Pittsburgh, PA) at the highest speed
(with the knob set at 10) for 48 h. The prepared lipid phase
was referred to as Capmul MCM:CA (1:1). Thereafter, Capmul
MCM:CA (1:1), Cremophor RH40 and/or PEG 400 were accu-
rately weighed into 20 ml scintillation vials. The resultant
mixtures in the vials were vortexed for 2 min and then
equilibrated on the wrist action shaker at the highest speed
at room temperature for 48 h to form blank SMEDDS.
2.4. Solubilization capacity study of blank SMEDDS for
model drugs
Solubilization capacity of the blank SMEDDS dispersions for
the model drugs was evaluated by determining the amount of
model drugs solubilized in the blank SMEDDS dispersions.
Therefore, equilibrium solubility of danazol, indomethacin or
haloperidol in blank SMEDDS dispersions as a function of
SMEDDS concentration was determined. Blank SMEDDS dis-
persions were obtained by dispersing 1, 2, 3, 4, or 5 g (0.4%, 0.8%,
1.2%, 1.6% or 2.0%, w/w) of blank SMEDDS into 250 ml of dis-
tilled water (pH 7.0), HCl buffer (pH 1.2), and phosphate buffer
(pH 6.8), respectively, using USP apparatus II (paddle method)
and the dispersion of blank SMEDDS was maintained at 37 °C
using a water heater for 60 min with the paddle rotated at
50 rpm.The buffers were prepared as directed in the USP [25].
Thereafter, 5 ml of the resultant blank SMEDDS dispersions was
taken and placed into a 20 ml scintillation vial. An excess
amount of danazol, indomethacin or haloperidol was placed
in the scintillation vial which was then shaken in a water bath
shaker (New Brunswick Scientific, Edison, NJ) at 200 rpm and
37 °C for 48 h to achieve equilibrium solubility of the three drugs
in the blank SMEDDS dispersions. The samples were filtered
using a 0.45 μm polypropylene filter and aliquots were diluted
with the mobile phase for HPLC analysis of drug content. In
the case of haloperidol, following filtration, samples were diluted
with a mixture of acetonitrile and 50 mM sodium acetate buffer
(pH 3.5) (70:30, v/v) for HPLC analysis.
2.5. Preparation of drug-loaded SMEDDS
The excipient composition of drug-loaded SMEDDS formula-
tions remained the same as blank SMEDDS formulations
(blank F5:5 and F4.5:4.5:1). The amount of model drug (i.e.,
danazol, indomethacin or haloperidol) to be loaded was
determined based on the outcomes of solubilization capacity
studies. Drug-loaded SMEDDS formulations were prepared
using the same preparation method of blank SMEDDS except
that the model drugs were added into the resultant mixtures
of blank SMEDDS before vortex and equilibration steps.
Table 1 – Composition of blank and drug-loaded SMEDDS formulations F5:5 and F4.5:4.5:1.
Composition Blank
SMEDDS
Drug-loaded SMEDDS
Danazol Indomethacin Haloperidol
Formulation F5:5
Capmul MCM:CA (1:1)a 50% 50% 50% 50%
Cremophor RH40 50% 50% 50% 50%
Drug 4.75 mg/g 18 mg/g 32.5 mg/g
Formulation F4.5:4.5:1
Capmul MCM:CA (1:1)a 45% 45% 45% 45%
Cremophor RH40 45% 45% 45% 45%
PEG 400 10% 10% 10% 10%
Drug 4 mg/g 15.5 mg/g 29 mg/g
a Mixture of Capmul MCM and caprylic acid at the ratio of 1:1.
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2.6. Dispersion/precipitation study of drug-loaded
SMEDDS
Drug-loaded SMEDDS formulations were subjected to
dispersion/precipitation study in distilled water (pH 7.0), HCl
buffer (pH 1.2) and phosphate buffer (pH 6.8), respectively.
The dispersion/precipitation study was performed using USP
apparatus II (paddle method). One gram (∼1 ml) of drug-
loaded SMEDDS formulations was accurately weighed in a
plastic weighing boat which was placed into the bottom of
dissolution vessel, containing 250 ml of dispersion medium,
using TDT-08 L Dissolution Tester (Pharma Alliance Group,
Valencia, CA). The volume of 250 ml aqueous medium was
used for dispersion study as per the solubility requirement
of BCS [15]. The paddle speed was set at 50 rpm and the
dispersion medium was maintained at 37 °C using a water
heater. Samples (2 ml each) were withdrawn at 10, 20, 30, 60,
90 and 120 min for dispersion study in HCl buffer and up to
240 min in distilled water and phosphate buffer. The samples
were processed and analyzed using the same methodology
as described in solubilization capacity study. No replacement
was made after sampling in this study, because addition of
fresh medium would dilute SMEDDS in the dispersion and
potentially decrease its capability of maintaining the drug in
the dispersion.
2.7. Droplet size analysis
A DelsaNano C particle size analyzer (Beckman Coulter Inc.,
Brea, CA) was used to measure the droplet size of the formed
dispersions for drug-loaded SMEDDS formulations in various
aqueous media. One gram of drug-loaded SMEDDS formula-
tions was dispersed in 250 ml of distilled water (pH 7.0), HCl
buffer (pH 1.2) or phosphate buffer (pH 6.8) using the same USP
apparatus II setup as for obtaining blank SMEDDS disper-
sions to obtain drug-loaded SMEDDS dispersions.Approximately
2–3 ml of samples was taken for droplet size analysis. Blank
SMEDDS dispersions formed in distilled water, HCl buffer and
phosphate buffer were also prepared using the same USP ap-
paratus II setup and droplet size was determined for
comparison.
3. Results and discussion
3.1. Solubilization capacity study of blank SMEDDS for
model drugs
Solubilization capacity of blank SMEDDS formulations for
danazol, indomethacin and haloperidol upon dispersion in
distilled water, HCl buffer and phosphate buffer, respectively,
was determined. Danazol has an aqueous solubility of 0.42 μg/
ml. Linear relationship between solubilization of danazol
and SMEDDS concentration was observed in all three aqueous
media for both blank F5:5 and F4.5:4.5:1 (Fig. 1). The solubili-
zation of danazol for blank F5:5 and F4.5:4.5:1 increased to 35
(±1.2)–258 (±5.5) μg/ml and 32 (±1.8)–222 (±3.8) μg/ml in dis-
tilled water, to 33 (±1.7)–222 (±3.8) μg/ml and 30 (±1.5)–204
(±5.9) μg/ml in HCl buffer, and to 19 (±1.2)–154 (±4.8) μg/ml
and 16 (±2.1)–149 (±5.0) μg/ml in phosphate buffer, respec-
tively, when the concentrations of SMEDDS were increased
from 0.4% to 2.0%.
Solubilization of indomethacin was found to have linear re-
lationship with the SMEDDS concentration in distilled water
and HCl buffer but not in phosphate buffer (Fig. 2). The intrin-
sic aqueous solubility of indomethacin for blank F5:5 and
F4.5:4.5:1 was determined to be 0.9 μg/ml. The solubilization
of indomethacin increased to 72 (±3.3)–541 (±15.1) μg/ml and
62 (±2.3)–448 (±9.0) μg/ml in distilled water, to 78 (±0.5)–454
(±18.8) μg/ml and 64 (±2.4)–446 (±3.3) μg/ml in HCl buffer, and
to 548 (±13.6)–668 (±18.8) μg/ml and 512 (±5.4)–624 (±7.9) μg/
ml in phosphate buffer, respectively, when the concentrations
of SMEDDS were increased from 0.4% to 2.0%.
Solubilization of haloperidol was found to have linear re-
lationship with SMEDDS concentration in distilled water and
HCl buffer but not in phosphate buffer (Fig. 3). In comparison
to its intrinsic aqueous solubility of 3.5 μg/ml, the solubiliza-
tion of haloperidol for blank F5:5 and F4.5:4.5:1 increased to
1401 (±10)–5988 (±208) μg/ml and 1248 (±20)–5602 (±154) μg/ml
in distilled water, to 1202 (±65)–1819 (±70) μg/ml and 1181 (±66)–
1662 (±93) μg/ml in HCl buffer, and to 130 (±6)–4426 (±8) μg/ml
and 116 (±1)–3890 (±67) μg/ml in phosphate buffer, respec-
tively, when the concentrations of SMEDDS were increased from
0.4% to 2.0%.
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Fig. 1 – Effect of SMEDDS concentration on danazol
solubilization capacity upon dispersion of blank F5:5 and
F4.5:4.5:1 in distilled water, HCl buffer and phosphate
buffer, respectively (data shown as mean ± standard
deviation, n = 3).
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3.2. Effect of ionization of drug on drug solubilization
behavior in SMEDDS
The solubilization behavior of danazol, indomethacin and halo-
peridol in the same blank SMEDDS dispersion exhibited vast
differences due to various degree of ionization of the three
drugs. A mathematical model has been proposed in the lit-
erature to explain the solubilization behavior of a weak acidic
drug, flurbiprofen, in pH-surfactant solutions [21]. In this model,
the total solubilization of the drug is considered as the com-
bined effects of pH and micellization. To better understand
ionization of drug on drug solubilization behavior in SMEDDS,
the published model was modified and utilized for all the three
drugs. In this modified model, it is assumed that four drug-
related species are considered to have contribution to the total
solubilization of the drug (Fig. 4). Du and Di represent union-
ized and ionized drugs diffused out from drug-loaded SMEDDS
and then solubilized in the aqueous medium upon disper-
sion of drug-loaded SMEDDS, respectively. Du-SMEDDS and Di-SMEDDS
represent unionized and ionized drugs remained in the formed
oil microdroplets upon dispersion of drug-loaded SMEDDS in
the aqueous medium, respectively. Therefore, the total drug
solubilization can be expressed as follows:
D D D D Dtotal u i u SMEDDS i SMEDDS= + + +− − (1)
For a neutral drug like danazol, no ionization of the drug
was expected in the aqueous medium. The solubilization of
the drug was contributed by Du and Du-SMEDDS. Because danazol
has a very poor aqueous solubility (Du), solubilization of danazol
in SMEDDS dispersions was essentially contributed by SMEDDS
components and their concentrations (Du-SMEDDS). As a result,
linear relationship between solubilization and SMEDDS con-
centrations was observed in all aqueous media at various pHs.
The solubilization enhancement in phosphate buffer was less
pronounced than that observed in distilled water and HCl buffer.
This could be due to the fact that high pH causes ionization
of caprylic acid, leading to partial loss of hydrophobic com-
ponents which results in lower solubilization capacity in
phosphate buffer.
For a weak acidic drug like indomethacin, when in equi-
librium, Du is the intrinsic aqueous solubility, and Di can be
determined using following equation [11,26]:
D Di u pH pKa= ⋅ −10 (2)
When the blank F5:5 and F4.5:4.5:1, regardless of the
SMEDDS concentration used, were dispersed in distilled water,
the pH of dispersions decreased to around 4 due to the
acidity of caprylic acid. However, when the blank SMEDDS
formulations were dispersed in HCl buffer, the pH of the
dispersions remained 1.2 due to the buffering effect of HCl
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Fig. 2 – Effect of SMEDDS concentration on indomethacin
solubilization capacity upon dispersion of blank F5:5 and
F4.5:4.5:1 in distilled water, HCl buffer and phosphate
buffer, respectively (data shown as mean ± standard
deviation, n = 3).
Fig. 3 – Effect of SMEDDS concentration on haloperidol
solubilization capacity upon dispersion of blank F5:5 and
F4.5:4.5:1 in distilled water, HCl buffer and phosphate
buffer, respectively (data shown as mean ± standard
deviation, n = 3).
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buffer. Because pKa of indomethacin is 4.5 and Du of indo-
methacin is small (0.9 μg/ml), Di was small at pH 4 and 1.2.
Hence, the solubilization of indomethacin in distilled water
and HCl buffer dispersions was predominantly attributed to
the SMEDDS components and their respective concentra-
tions (Du-SMEDDS and Di-SMEDDS). Therefore, similar linear
solubilization profiles between drug solubilization and SMEDDS
concentration were observed in distilled water and HCl buffer
(Fig. 2). However, in phosphate buffer, solubilization of indo-
methacin was more complex because pH also plays an
important role in its solubilization (Di and Di-SMEDDS). A substan-
tial increase in solubilization of indomethacin was observed
at SMEDDS concentration of 0.4% due to the high pH of the
dispersion (pH 6.6) and SMEDDS components. However, the
dispersion of 0.8% of blank SMEDDS in phosphate buffer
resulted in a dispersion having pH 6.4 due to the acidity of
caprylic acid. Because the solubilization of indomethacin is
sensitive to pH change at high pH range, the increase of
indomethacin solubilization provided by increasing SMEDDS
concentration from 0.4% to 0.8% was not enough to compen-
sate for the decrease of solubilization due to the decrease of
pH in the dispersions. Consequently, declines of indometha-
cin solubilization were observed. Thereafter, the dispersions
of 1.2%–2.0% of blank SMEDDS formulations in phosphate
buffer maintained pH around 6.4 due to buffering effect of
phosphate buffer and association of caprylic acid at rela-
tively high concentration. Consequently,Di remained unchanged
and solubilization of the drug was mainly attributed to
Du-SMEDDS and Di-SMEDDS but not the small Du. As a result,
indomethacin solubilization increased along with SMEDDS
concentration increasing from 0.8% to 2.0%.
For a weak basic drug like haloperidol, when in equilib-
rium,Du is the intrinsic aqueous solubility and Di can be written
as follows [11,26]:
D Di u pKa pH= ⋅ −10 (3)
As described previously, when the blank F5:5 and F4.5:4.5:1,
regardless of the SMEDDS concentration used, were dis-
persed in distilled water and HCl buffer, the pH of dispersions
remained around 4 and 1.2, respectively. Hence, Di remained
constant and Du is constant. As a result, haloperidol solubili-
zation increased linearly with SMEDDS concentration in distilled
water and HCl buffer (Fig. 3). However, in phosphate buffer,
the pH of dispersions was decreased to 6.6 at SMEDDS
concentration of 0.4% and then maintained at 6.4 from 0.8%
to 2.0%. Di was small at this pH range. Haloperidol solubiliza-
tion was therefore predominantly attributed to Du-SMEDDS and
Di-SMEDDS. Consequently, haloperidol solubilization increased
along with the increase of SMEDDS concentration. Since
caprylic acid ionizes to caprylate at high pH, the overall
solubilization of haloperidol in phosphate buffer was less
pronounced than that observed in distilled water. In addition
to its direct effect on Di and Di-SMEDDS, pH also indirectly
affects hydrogen bond formation between weak acid and
weak basic drug which has been suggested to be responsible
for haloperidol solubilization [27]. In distilled water, in addi-
tion to pH and SMEDDS components, the hydrogen bond
formation between caprylic acid and haloperidol contributes
greatly for the pronounced solubilization enhancement. In
HCl buffer, caprylic acid was predominantly protonated and
less likely to form hydrogen bond with haloperidol. There-
fore, a substantial increase was obtained at SMEDDS
concentration of 0.4% due to pH effect. Thereafter, drug
solubilization increases linearly with the SMEDDS concentra-
tion at a much slower rate. However, in phosphate buffer,
caprylic acid was predominantly ionized to caprylate at
SMEDDS concentration of 0.4% and hydrogen bond forma-
tion was not favorable; hence, less drug solubilization was
observed. Thereafter, at SMEDDS concentrations from 0.8% to
2.0%, ionization of caprylic acid might be impeded due to
buffering effect of the aqueous medium and association of
SMEDDS components at high concentrations. Therefore, hy-
Fig. 4 – Schematic representation of ionization of drug on drug solubilization upon dispersion of drug-loaded SMEDDS in
aqueous media at various pHs (Du and Di: unionized and ionized drugs diffused out from drug-loaded SMEDDS and then
solubilized in the aqueous medium upon dispersion of drug-loaded SMEDDS; Du-SMEDDS and Di-SMEDDS: unionized and ionized
drugs remained in the formed oil microdroplets upon dispersion of drug-loaded SMEDDS in aqueous medium).
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drogen bond formation is progressively favored and
consequently, more extensive drug solubilization enhance-
ment was observed.
3.3. Preparation of drug-loaded SMEDDS
The composition of drug-loaded SMEDDS formulations was
listed in Table 1. Drug loading was calculated based on the
lowest solubilization capacity for each drug in blank SMEDDS
dispersions. For example, one gram of blank F5:5 dispersed in
phosphate buffer exhibited the lowest solubilization capacity
for danazol at 19 μg/ml. Therefore, 4750 μg (19 μg/ml × 250 ml)
or 4.75 mg danazol was loaded per gram of blank F5:5 for the
preparation of danazol-loaded SMEDDS formulation F5:5. Simi-
larly, 4 mg danazol was loaded per gram of blank F4.5:4.5:1.
Using the same concept, the amounts of indomethacin to be
loaded in blank SMEDDS formulations were calculated to be
18 mg/g and 15.5 mg/g for indomethacin-loaded F5:5 and
F4.5:4.5:1, respectively. And, the amounts of haloperidol to be
loaded were 32.5 mg/g and 29 mg/g for haloperidol-loaded F5:5
and F4.5:4.5:1, respectively.
Typically, the amount of drug to be loaded in blank SMEDDS
formulations is based on drug solubility in individual excipi-
ents or in the mixtures of SMEDDS compositions (e.g., mixture
of lipids and surfactants). The advantage of this method is to
ensure that the drug is completely solubilized in the SMEDDS
formulations [3]. However, drug solubilized in the SMEDDS for-
mulations does not necessarily guarantee drug solubilized upon
dispersion into aqueous medium. This is because hydro-
philic excipients (e.g., surfactants, and/or co-solvent) contained
in the SMEDDS formulations might lose some of solubiliza-
tion capacity upon diluting with aqueous medium due to
relocation of the hydrophilic molecules in the aqueous medium
[3,28]. For example, extensive drug precipitation was ob-
served upon dispersion of fenofibrate-loaded SMEDDS
formulations in water, for which fenofibrate was loaded based
on its solubility in the lipid components [28].
Therefore, to avoid any possible drug precipitation during
dispersion/precipitation study, drug loading was not based on
their solubility in the SMEDDS components but based on the
lowest solubilization capacity provided by blank SMEDDS
dispersions.
3.4. Dispersion/precipitation study of drug-loaded
SMEDDS
All drug-loaded SMEDDS formulations, indomethacin powder
and haloperidol powder except for danazol powder were dis-
persed in distilled water, HCl buffer and phosphate buffer to
evaluate drug dispersion/precipitation profiles at various pH.
Danazol-loaded SMEDDS formulations were dispersed in the
three aqueous media because they contain caprylic acid and
are subject to pH effect. Danazol powder was dispersed only
in distilled water because it is pH independent. Overall, in com-
parison to their respective drug powder, the use of SMEDDS
formulations significantly enhanced solubilization of danazol,
indomethacin, and haloperidol.
For danazol-loaded F5:5 and F4.5:4.5:1 (Fig. 5), danazol re-
mained dispersed and solubilized in all three aqueous media
and no drug precipitation was observed up to 4 h. However,
for danazol powder, very little or no drug solubilization was
detected in distilled water.
For indomethacin-loaded F5:5 and F4.5:4.5:1 (Fig. 6), indo-
methacin was well dispersed and solubilized in all three
aqueous media and no drug precipitation was observed up to
4 h. In contrast, indomethacin powder was poorly solubilized
in distilled water (from 0.1 μg/ml to 5 μg/ml at 240 min) and
HCl buffer (not detectable). Indomethacin powder was only well
solubilized in phosphate buffer due to its high solubility at this
pH (630 μg/ml).
Similarly, for haloperidol-loaded F5:5 and F4.5:4.5:1 (Fig. 7),
haloperidol was well dispersed and solubilized in all three
aqueous media and no drug precipitation was observed up to
4 h. On the other hand, haloperidol powder showed very poor
solubilization in either distilled water (not detectable) or phos-
phate buffer (not detectable). Haloperidol powder only showed
good solubilization in HCl buffer due to its high solubility at
this pH (1074 μg/ml).
Despite the fact that the SMEDDS significantly enhanced
solubilization of danazol, indomethacin and haloperidol during
dispersion of drug-loaded SMEDDS, drug loading in SMEDDS
0 30 60 90 120 150 180 210 240
D
an
az
ol
 c
on
ce
nt
ra
tio
n 
(µ
g/
m
l)
0
5
10
15
20
25
Distilled water
HCl buffer
Phosphate buffer
Distilled water
Time (min)
0 30 60 90 120 150 180 210 240
0
5
10
15
20
25
F5:5
F4.5:4.5:1
Fig. 5 – Danazol dispersion/precipitation profiles of
danazol-loaded SMEDDS formulations F5:5 and F4.5:4.5:1
(filled symbols), as well as danazol powder (open symbols),
dispersed in distilled water, HCl buffer, and phosphate
buffer, respectively (data shown as mean ± standard
deviation, n = 3; danazol powder was dispersed only
distilled water).
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formulations and the resultant dispersion/precipitation pro-
files of the three drugs exhibited vast differences. For
formulation F5:5, drug loading was 4.75, 18 and 32.5 mg/g for
danazol, indomethacin and haloperidol, respectively. For for-
mulation F4.5:4.5:1, drug loading was 4, 15.5 and 29 mg/g for
the three drugs, respectively.This is because drug loading was
calculated based on solubilization of the three drugs pro-
vided by blank SMEDDS dispersions. As discussed above, the
solubilization behavior of the drugs in blank SMEDDS disper-
sions was ascribed to ionization of the drugs. Non-ionizable
neutral danazol exhibited much less pronounced drug solu-
bilization enhancement than ionizable weak acidic/basic drugs
(indomethacin and haloperidol). Correspondingly, drug loading
was much lower for danazol than that of indomethacin and
haloperidol in SMEDDS formulations. Similarly, dispersion/
precipitation profiles were much less pronounced for danazol
than that for indomethacin and haloperidol.
3.5. Droplet size analysis
The droplet size of the formed microemulsions upon disper-
sion of one gram of drug-loaded SMEDDS formulations in 250ml
distilled water, HCl buffer and phosphate buffer was deter-
mined and compared with the respective blankmicroemulsions.
As outlined in Table 2, in comparison to the blank
microemulsions, incorporation of danazol in the SMEDDS for-
mulations did not significantly change the droplet size of the
microemulsions. The droplet sizes of microemulsions from
danazol-loaded F5:5 were 182, 177 and 60 nm in distilled water,
HCl buffer and phosphate buffer, respectively, and are similar
to 179, 175 and 64 nm for the corresponding blank
microemulsions. In the case of danazol-loaded F4.5:4.5:1, 129,
147 and 36 nm were obtained for microemulsions in the three
aqueous media, respectively, which are similar to 133, 155 and
33 nm for the corresponding blank microemulsions.
In contrast to danazol, loading indomethacin or haloperi-
dol in the SMEDDS formulations was observed to reduce the
droplet size of the formedmicroemulsions. For formulation F5:5,
loading indomethacin or haloperidol resulted inmicroemulsions
with droplet sizes of 83 nm and 79 nm or 93 nm and 102 nm
in distilled water and HCl buffer, respectively, which are much
smaller than 179 nm and 175 nm for the corresponding blank
microemulsions. Similarly, for formulation F4.5:4.5:1, loading
indomethacin or haloperidol resulted in droplet sizes of 89 nm
and 76 nm or 93 nm and 88 nm in distilled water and HCl buffer,
respectively, which are smaller than 133 nm and 155 nm for
the corresponding blank microemulsions. Interestingly, loading
indomethacin or haloperidol did not appear to reduce the
Fig. 6 – Indomethacin dispersion/precipitation profiles of
indomethacin-loaded SMEDDS formulations F5:5 and
F4.5:4.5:1 (filled symbols), as well as indomethacin powder
(open symbols), dispersed in distilled water, HCl buffer, and
phosphate buffer, respectively (data shown as
mean ± standard deviation, n = 3).
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Fig. 7 – Haloperidol dispersion/precipitation profiles of
haloperidol-loaded SMEDDS formulations F5:5 and
F4.5:4.5:1 (filled symbols), as well as haloperidol powder
(open symbols), dispersed in distilled water, HCl buffer, and
phosphate buffer, respectively (data shown as
mean ± standard deviation, n = 3).
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droplet size of microemulsions formed in phosphate buffer.
Droplet size of 55 nm or 76 nmwas obtained for indomethacin-
or haloperidol-loaded F5:5 microemulsions in comparison to
64 nm for the corresponding blank microemulsion. Similarly,
droplet size of 33 nm or 45 nmwas observed for indomethacin-
or haloperidol-loaded F4.5:4.5:1 in comparison to 30 nm for the
corresponding blank microemulsion.
The results of droplet size analysis indicate that ioniza-
tion of drug might be one of the inducing factors for droplet
size reduction of themicroemulsions.Weak acidic or basic drugs
are inherently surface-active reagents which influence phase
behavior (e.g., droplet size and shape) of lipid/surfactant/
water systems [10,12]. It has been suggested that solubilization
of drugs changes the size or shape of the lipid/surfactant mi-
crostructures (e.g., microemulsions) only when the drug
molecules are residing at the interface of the lipid/surfactant
microstructures [10]. Therefore, no change in droplet size for
danazol-loaded microemulsions indicates that solubilization
of danazol mostly occurs in the lipid core but not at the in-
terface of the formed microstructures. Moreover, the droplet
size reduction observed for indomethacin- or haloperidol-
loadedmicroemulsions suggests that solubilization of the drugs
might be predominantly at the interface of the microemulsions.
The solubilized drug molecules might intercalate into the in-
terface of the microemulsions due to their surface-active
properties, acting as co-surfactant to reduce the droplet size.
In addition to drug effect, pH plays a major role in influenc-
ing the droplet size of microemulsions. As listed in Table 2, all
blank or drug-loaded microemulsions formed in phosphate
buffer exhibited much smaller droplet size than that of the
microemulsions formed in distilled water and HCl buffer. At
high pH, caprylic acid ionizes to caprylate which leads to
reduced hydrophobic volume in the system. Also the resul-
tant caprylate acts as co-surfactant to further reduce the droplet
size of the microemulsions. Furthermore, pH effect might out-
weigh drug effect to reduce the droplet size small enough,
leaving no space for drug effect. Consequently, no droplet size
reduction was observed between drug-loaded microemulsions
and the respective blank microemulsions in phosphate buffer.
4. Conclusion
The current investigation has explored the impact of ioniza-
tion of drug, using danazol, indomethacin and haloperidol as
model drugs, on drug solubilization in SMEDDS prepared using
Capmul MCM and caprylic acid.The solubilization behavior of
neutral, weak acidic and weak basic drugs in blank SMEDDS
dispersions was evaluated using a modified mathematical
model and the differences in drug solubilization were attrib-
uted to various degree of drug ionization. It was found that upon
dispersion of drug-loaded SMEDDS in aqueous media at various
pHs, four drug-related species (Du,Di, Du-SMEDDS and Di-SMEDDS) con-
tribute to total drug solubilization. Correspondingly, drug loading
and drug dispersion/precipitation profiles of drug-loaded
SMEDDS for neutral, weak acidic and weak basic drugs also
exhibited distinct differences. Furthermore, weak acidic/
basic drugs but not neutral drugs reduced the droplet size of
the microemulsions, indicating that ionization of drug also had
significant impact on droplet size formation of the SMEDDS
due to various intermolecular forces between the drugs and
SMEDDS components.
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